Many well-differentiated neuroendocrine tumors express somatostatin receptors on their cell surface. German university nuclear-medicine departments use Ga-68-labeled somatostatin analogues such as DOTATOC or DOTA-i-TATE to visualize that receptor expression with PET/CT. Heidelberg explicitly links DOTATOC PET/CT to PRRT eligibility, while Ulm routinely lists Ga-68 DOTA-i-TATE PET/CT for neuroendocrine tumors.
The scan answers a receptor-expression question
Somatostatin-receptor PET/CT is different from FDG PET/CT. It is designed to show whether tumor deposits express sufficient somatostatin receptors and can contribute to staging, treatment planning and theranostic assessment in suitable neuroendocrine tumors.
Why it matters before PRRT
Heidelberg states that sufficient uptake on somatostatin-receptor imaging is a prerequisite for PRRT. A receptor-positive scan supports the treatment assessment but does not by itself establish that PRRT is the correct next treatment; tumor origin, grade, disease extent, previous therapy and organ function also matter.
Records to prepare for review
The nuclear-medicine team needs the full NET context rather than the PET request alone.
- Pathology confirming the neuroendocrine tumor and tumor grade
- Primary tumor site and current disease stage
- Previous CT, MRI, PET/CT or somatostatin-receptor imaging
- Surgery, somatostatin-analogue, chemotherapy or targeted-treatment history
- Current medication including long-acting somatostatin analogues
- Recent kidney and liver function, blood counts and relevant tumor markers
- The clinical question: staging, response assessment or PRRT eligibility
Medication timing may matter
Somatostatin-analogue treatment can affect scheduling around receptor imaging and PRRT pathways. International patients should send the exact product, dose and last administration date and follow the imaging center's preparation instructions rather than stopping medication independently.
Ask for original images and a downstream plan
Request the PET/CT report and original DICOM images for the oncologist or NET team continuing care. Before travelling, clarify whether the scan is part of a broader multidisciplinary NET review and whether a positive result would lead to PRRT assessment or another treatment decision.
Official sources
Sources last checked 2026-08-30. Diagnostic indications and preparation requirements can change, so confirm current instructions with the imaging center before travelling.